Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria
14/6 16:50
Barzolvolimab significantly reduced angioedema symptoms in CSU patients after 52 weeks, demonstrating clinical efficacy and improved quality of life....